MedTrace Logo

Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems

NCT03961776 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 39

Last updated 2021-05-06

No results posted yet for this study

Summary

feasibility of using a diffusion sequence of a MRgRT system as an early marker of treatment response during nRCT of rectal adenocarcinoma.

Conditions

  • Rectal Adenocarcinoma

Interventions

DEVICE

MRI-guided radiotherapy by on-board DWI sequences

The radiotherapy treatment will be delivered on the MRI-guided radiotherapy platform. The on-board DWI sequences will be performed every three fractions in addition to the treatment session and will last approximately 3-4 minutes.

Sponsors & Collaborators

Principal Investigators

  • Marguerite TYRAN, MD · Institut Paoli-Calmettes

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-08
Primary Completion
2022-05-31
Completion
2027-05-31
FDA Device
Yes

Countries

  • United States
  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03961776 on ClinicalTrials.gov